Neuroendocrine Tumours on the Rise, Eight-year Study Assesses GEP-NET Management Trends

Neuroendocrine Tumours on the Rise, Eight-year Study Assesses GEP-NET Management Trends

An eight-year observational, multi-centre, registry study was undertaken to assess the incidence and regional trends in diagnosis, clinical management and outcome assessments of patients with gastroenteropancreatic neuroendocrine tumours (GEP-NET) in the Asia-Pacific region, the Middle East, Turkey and South Africa. The pancreas was the most commonly reported primary tumour site, with abdominal pain being the most commonly reported symptom. Surgery was the mostcommon initial treatment, followed by treatment with somatostatin analogues. This analysis highlighted the need for improvements in clinical practice to ensure better evaluation and treatment management.

Modern Medicine – Issue 2 2022